Innovating Cure & Care to make patients’ lives better
We are a modern chemical-pharmaceutical company, founded on the history and values of an Italian family owned enterprise, with ambitious plans for growth
We look to the future, researching new cure and treatment solutions for specialized diseases such as Parkinson's and severe respiratory disease
Zambon’s Presence in the USA
Over the past few years, we have been steadily building our presence in the US through acquisition, R&D efforts, collaborative partnerships, and relationships with top scientific leaders, policymakers and patient organizations.
Bronchiolitis Obliterans Syndrome (BOS) is a rare and severe respiratory disease that commonly affects people following lung or allogeneic hematopoietic stem cell transplant.
Non-cystic Fibrosis Bronchiectasis (NCFB) is a serious respiratory disease characterized by chronic inflammation, wall thickening and dilatation of the airways.
Work with us
We want people who make the difference through a make-it-happen approach based on company ethics. We recognize merits, developing talents and taking good care of our people.
News & Media
- May 12, 2022 - Zambon Announces Attendance at American Thoracic Society (ATS) 2022 Annual Meeting
Download press release
- Zambon to present data on lung transplantation trends and survival rates in Europe at ISHLT 2022
- Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFB)
- Positive Results from Phase 3 PROMIS-I Study of CMS I-neb® in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at European Respiratory Society (ERS) Annual Meeting
We will be at ISHLT 2022 in Boston!
April 27-30, 2022 (Booth 526)
We will be at ATS 2022 in San Francisco!
May 13-18, 2022 (Clinical Trials Booth 10)